Avantor, Inc. (AVTR)

Avantor is a turnaround play in life sciences distribution and manufacturing, trading at a historically low valuation after a 50% stock decline. New management is executing a Revival program targeting $400M in cost savings, debt reduction, and organizational restructuring to restore growth and margins. 2026 guidance remains cautious, with revenue and adjusted EPS expected to decline, but stabilization and growth are anticipated in 2027.

Avantor, Inc. (NYSE: AVTR - Get Free Report) Director Gregory Lucier purchased 50,000 shares of the firm's stock in a transaction dated Thursday, February 19th. The stock was acquired at an average price of $9.16 per share, for a total transaction of $458,000.00. Following the purchase, the director owned 50,000 shares in the company, valued at

AVTR, CMCO and KHC have been added to the Zacks Rank #5 (Strong Sell) List on February 17th, 2026.

Avantor stock sinks 13% as Q4 earnings beat estimates, but revenues slip, margins contract and 2026 outlook signals more pressure ahead.

Avantor, Inc. (NYSE: AVTR - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 48,044 put options on the company. This represents an increase of approximately 1,025% compared to the typical volume of 4,270 put options. Avantor Trading Down 13.5% Shares of AVTR stock opened at $9.66 on

• Avantor shares are approaching critical lows. Why is AVTR stock at lows?

Avantor, Inc. (AVTR) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Avantor (AVTR) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.27 per share a year ago.

Revival program underway, including relaunch of VWR brand, implementation of critical manufacturing and supply chain improvements, and upgrades to e-commerce channel Fourth Quarter 2025 Net sales of $1.66 billion, decrease of 1%; organic decrease of 4% Net income of $52 million; Adjusted EBITDA of $252 million Diluted GAAP EPS of $0.08; adjusted EPS of $0.22 Operating cash flow of $153 million; free cash flow of $117 million Full Year 2025 Net sales of $6.55 billion, decrease of 3%; organic decline of 3% Net loss of $530 million; Adjusted EBITDA of $1,069 million Diluted GAAP loss per share of $0.78; adjusted EPS of $0.90 Operating cash flow of $624 million; free cash flow of $496 million RADNOR, Pa., Feb. 11, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its fourth fiscal quarter and year ended December 31, 2025.

Avantor (NYSE: AVTR - Get Free Report) and Selectis Health (OTCMKTS:GBCS - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends. Insider and Institutional Ownership 95.1% of Avantor shares are

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Investors interested in stocks from the Medical Services sector have probably already heard of Avantor, Inc. (AVTR) and Alignment Healthcare (ALHC). But which of these two stocks offers value investors a better bang for their buck right now?

Avantor (NYSE: AVTR - Get Free Report) and LifeMD (NASDAQ: LFMD - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 95.1% of Avantor shares are owned

NEW YORK, Jan. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Avantor, Inc. (NYSE: AVTR)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Avantor caused the company to misrepresent or fail to disclose that: (1) Avantor's competitive positioning was weaker than had been publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

New York, New York--(Newsfile Corp. - January 15, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Avantor, Inc. (NYSE: AVTR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Avantor caused the company to misrepresent or fail to disclose that: (1) Avantor's competitive positioning was weaker than had been publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.